(Q42977561)

12 November 2017

Update on alisporivir in treatment of viral hepatitis C. (English)

1 reference

12 November 2017

1 reference

1

Robert Flisiak

1 reference

12 November 2017

2

Jerzy Jaroszewicz

1 reference

12 November 2017

3

Iwona Flisiak

1 reference

12 November 2017

Tadeusz Łapiński

4

1 reference

PubMed ID

22316207

12 November 2017

language of work or name

English

0 references

publication date

8 February 2012

1 reference

Expert Opinion on Investigational Drugs

12 November 2017

1 reference

12 November 2017

21

1 reference

12 November 2017

375-382

1 reference

12 November 2017

3

1 reference

Evolving epidemiology of hepatitis C virus

12 November 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The global health burden of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Interferon-based therapy for chronic hepatitis C: current and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Dealing with the family: CD147 interactions with cyclophilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclophilin inhibitors in hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Specific incorporation of cyclophilin A into HIV-1 virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Extracellular cyclophilins contribute to the regulation of inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

High binding capacity of cyclophilin B to chondrocyte heparan sulfate proteoglycans and its release from the cell surface by matrix metalloproteinases: possible role as a proinflammatory mediator in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Multiple cyclophilins involved in different cellular pathways mediate HCV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

The Cyclophilin Inhibitor Debio-025 is a Potent Inhibitor of Hepatitis C Virus Replication in vitro With a Unique Resistance Profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.658641

10.1517/13543784.2012.658641

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference

PubMed ID

22316207